Bristol Myers Squibb, shared on LinkedIn:
“As the global oncology community gathers for IMS26, we’re reminded of the impact CAR-T Cell Therapy has already had on blood cancers.
But while progress has been made, multiple myeloma still remains largely incurable. Patients who relapse or become resistant face a critical need for new treatment options.
This is what drives our commitment to advancing research to navigate the complexities of multiple myeloma and other serious diseases. By focusing on differentiated targets, we aim to address treatment gaps and deliver improved outcomes for patients.
Learn how we’re advancing CAR T for patient populations in need:”
